title: Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
abstract: OBJECTIVE
  Efficacy and safety comparison of daclatasvir/asunaprevir (DCV + ASV) versus peginterferon-α/ribavirin (A/R) alone or combined with telaprevir, boceprevir, simeprevir or sofosbuvir in chronic genotype 1b hepatitis C virus infection.
  
  
  METHODS
  Network meta-analysis (NMA) and matching-adjusted indirect comparisons (MAICs).
  
  
  RESULTS
  Among treatment-naive patients, DCV + ASV demonstrated higher sustained virologic response (SVR) rates than telaprevir + A/R, boceprevir + A/R and A/R in NMA and MAICs and simeprevir + A/R in NMA. DCV + ASV among treatment-experienced patients had higher SVR rates than telaprevir + A/R, boceprevir + A/R, simeprevir + A/R and A/R in MAICs. DCV + ASV had lower adverse events rates than comparators.
  
  
  CONCLUSIONS
  DCV + ASV demonstrated superior efficacy and safety compared with A/R-based regimens.
authors.affiliation: Analysis Group, Inc., Boston, MA 02199, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Signorovitch
authors.affiliation: Analysis Group, Inc., Boston, MA 02199, USA.
authors.forename: Keith A
authors.initials: KA
authors.lastname: Betts
authors.affiliation: Analysis Group, Inc., Boston, MA 02199, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Song
authors.affiliation: Analysis Group, Inc., New York, NY, USA.
authors.forename: Rachael A
authors.initials: RA
authors.lastname: Sorg
authors.affiliation: Analysis Group, Inc., Boston, MA 02199, USA.
authors.forename: Junlong
authors.initials: J
authors.lastname: Li
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Ajay S
authors.initials: AS
authors.lastname: Behl
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Anupama
authors.initials: A
authors.lastname: Kalsekar
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D002219:Carbamates; D057186:Comparative Effectiveness Research; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007372:Interferons / Q000008:administration & dosage*; D007546:Isoquinolines / Q000008:administration & dosage*; D008297:Male; D011759:Pyrrolidines; D012254:Ribavirin / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D007546:Isoquinolines; D011759:Pyrrolidines; D013449:Sulfonamides; D012254:Ribavirin; D007372:Interferons; D014633:Valine; C549273:daclatasvir; C571889:asunaprevir
keywords: asunaprevir; daclatasvir; direct-acting antiviral agents; genotype 1b; hepatitis C